Heart disease risk in people newly diagnosed with type 2 diabetes in Southeast Asia
Reviews past records to describe heart disease risk in newly diagnosed type 2 diabetes.
Key facts
- Who runs it
- Novo Nordisk A/S
- Where
- Singapore, SingaporeSee the siteAlso in 3 other countries, 5 sites
- Trial code
- Registry title
- A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 13 Mar 2026
- Expected to end
- 27 Mar 2027
- Type of study
- Observational
- Treatments tested
- No treatment given
- Record updated
- 28 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at adults aged 40 to under 70 who were newly diagnosed with type 2 diabetes and started diabetes treatment in 2022 or 2023. It reviews their past medical charts.
- Age
- From 40 years up to under 70 years.
- Sex
- Men and women can join.
- Disease stage
- Newly diagnosed type 2 diabetes (T2DM), with anti-hyperglycemic treatment started between 1 January 2022 and 31 December 2023.
- Earlier treatment
- Cannot have been prescribed any anti-hyperglycemic medication before the first T2DM diagnosis.
Main reasons for not taking part
- Type 1 diabetes or gestational diabetes
- Pregnant women
- Existing atherosclerotic heart or blood vessel disease (coronary heart disease, stroke, transient ischemic attack, peripheral artery disease)
- Died within 12 months after the first T2DM diagnosis
- No visit 12 months (± 3 months) after the first T2DM diagnosis
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Aged greater than equal to (≥) 40 and less than (<) 70 years
- Male or female
- Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023
Who cannot take part
- Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM
- T1DM or gestational diabetes
- With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease
- If any exclusion criterion is met, the participant will be excluded from the study
- Pregnant women
- Died within 12 months after first diagnosis of T2DM
- Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
Where in Singapore
Also in 3 other countries, 5 sites
- SingaporeHospital not named in the registryContact: Novo NordiskTaking people
About the trial
What the trial wants to find out
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.
The group in the trial
- T2DM Cohort
Participants with T2DM identified in south asian countries.
Treatment: No treatment given
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Retrospective Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus Participants in Southeast Asia
- Plain-language title
- Heart disease risk in people newly diagnosed with type 2 diabetes in Southeast AsiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07532863, who can take part
- Record updated
- 28 July 2026